Groupe UIG’s Post

RNA - technology of the future in life sciences. Global RNA therapeutics market size was valued at USD 23,067.85 million in 2023, expected to reach USD 54,464.95 million in 2031. Factors impacting the global RNA therapeutics market include progress in RNA technology, augmented research funding, heightened incidence of chronic diseases, demand for personalized medicine, the effectiveness of RNA-based drugs in treating previously incurable conditions, and the substantial influence of regulatory support and collaborations among pharmaceutical firms contributing to market expansion. Read: https://lnkd.in/eAcWyKnK #sciencesdelavie #biotechnology #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #revolution #happy

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗖𝗲𝗹𝗹 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Cell Culture Market Size, Share & Trends Analysis Report By Product (Consumables, Sera, Media, Reagents, Bioreactor Accessories, Instruments, Bioreactors, Cell Culture Vessels, Cell Culture Storage Equipment, Cell Culture Supporting Instruments), By End User (Research Institutes, Pharmaceutical & Biotechnology Companies, Others), By Application (Stem Cell Technology, Cancer Research, Drug Screening and Development, Tissue Engineering & Regenerative Medicine, Others), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dyfDbVdy 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Syros Pharmaceuticals Takeda Synchron Synthego Corporation Synthekine Takeda Pharmaceuticals (formerly Nycomed) Tectonic Therapeutic, Inc. Teva Pharmaceuticals The Janssen Pharmaceutical Companies of Johnson & Johnson Thermo Fisher Scientific Thymmune Therapeutics Torque Bio Tr1X   TransCode Therapeutics, Inc. TRIO - Translational Research in Oncology Transomic Technologies Inc. Tune Therapeutics UCB Ultragenyx Umoja Biopharma Unicycive Therapeutics Varian Vaxess Technologies Velia   Venatorx Pharmaceuticals, Inc. Ventus Therapeutics Versatope Therapeutics Vertex Pharmaceuticals Verve Therapeutics ViaCyte Vistagen VitaCyte Vyant Bio Werewolf Therapeutics Wugen WuXi Advanced Therapies WuXi Biologics XBiotech USA, Inc. Xylome   #cellculture #science #cellbiology #research #biology #molecularbiology #laboratory #biotechnology #cellculturelab #phd #phdlife #cells #womeninscience #chemistry #cell #phdstudent #laboratorylife #genetics #scientist #womeninstem #lab #pharmacology #biotech #drugdiscovery #cancerresearch #lablife #sciencelife #neurons #womendoingscience #scientistlife

scFv antibodies advantage: Size and Solubility: scFv antibodies are smaller than full-length antibodies, making them more accessible to target molecules. Their compact structure also enhances solubility, enabling easier production and purification. https://lnkd.in/grSMc4Xm #scFv #antibodies #production #purification #AlphaLifetech #antibodylibrary #biotechnology #research #science #innovation #biotech #molecularbiology #medicalscience #proteinengineering #immunotherapy #biopharmaceuticals

Primary Cells Market Worth $2.8 Billion Download a PDF Brochure: https://lnkd.in/dMZrD9ev The growth of this market can be attributed to factors such as the is government investments for cell-based research, rising growth in pharmaceutical & biotechnology industries, increasing cancer research, increasing demand for monoclonal antibodies, increasing demand for personalized medicine, and growing advantages of primary human cells over cell lines. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Thermo Fisher Scientific Merck KGaA, Darmstadt, Germany Lonza Cell Biologics, Inc PromoCell HemaCare Corporation, a Charles River Company ZenBio STEMCELL Technologies Corning Incorporated AllCells ATCC-American-Type-Culture-Collection Axol Bioscience Ltd. iXCells Biotechnologies Neuromics BioIVT ScienCell Research Laboratories ProMab Biotechnologies, Inc. Creative Bioarray BPS Bioscience Inc. Epithelix AcceGen AMSBIO Kosheeka Other Companies that are Operating in this Market Globally: CGT Global BioLamina Clean Cells Polish Stem Cells Bank (PBKM)/ FamiCord Group Kite Pharma Ginkgo Bioworks, Inc. Editas Medicine Molecular Devices Poseida Therapeutics, Inc.  Atara Biotherapeutics  INOVIO Pharmaceuticals, Inc. Fate Therapeutics Inc. Discovery Life Sciences ATCC Akron Bio Epic Sciences Gritstone bio #PrimaryCells #HealthTech #Biotechnology #LifeSciences #MedicalResearch #CellBiology #HealthcareInnovation #CellCulture #BiomedicalResearch #StemCells #ScientificResearch #ClinicalResearch #LabTech #HealthcareTechnology #BioTech #RegenerativeMedicine #CellTherapy #Pharmaceuticals #TissueEngineering #MarketResearch

scFv antibodies advantage: Size and Solubility: scFv antibodies are smaller than full-length antibodies, making them more accessible to target molecules. Their compact structure also enhances solubility, enabling easier production and purification. https://lnkd.in/g_ED5EFP #scFv #antibodies #production #purification #AlphaLifetech #antibodylibrary #biotechnology #research #science #innovation #biotech #molecularbiology #medicalscience #proteinengineering #immunotherapy #biopharmaceuticals

Greetings, fellow researchers! Need top-tier research execution for your next project? Looking for a reliable Contract Research Organization (CRO)to manage your entire research journey? We've got you covered! At SCILIV Pvt Ltd we offer comprehensive research solutions, from crafting the perfect study design to delivering insightful data analysis. Our commitment: ✅ Quality ✅ Accuracy ✅ Timely Delivery Visit our website sciliv.org to learn more about our services. #SCILIVPVTLTD #CRO #research #liveR&D #preclinicaltrials #science #biomedical #healthcare #biomaterials #OrthopedicImplants #WoundcareProducts #DentalImplants #Nutraceuticalproducts #KitsforCellBiology #KitsforMolecular Biology #KitsforMicrobiology #KitsforPharmaceuticals #Research #cellculture #cellbiology #molecularbiology #microbiology #nanotechnology #pharmaceutical #pharmacology #tissueengineering #qrtpcr #PCR #uvvisspectrophotometry #biomolecules #bioanalytical #cancer #oncology #bone #medicinalchemistry #iBrightImagingSystems #thermoscientific #olympus #microscope #invitrogen #Countess3AutomatedCellCounter #nutraceuticals #phytochemicals #flowcytometry #co2incubatorthermoscientific #Zebrafishforcancerstudy #Mosquitolarvicidalactivity #Celegans #CAMtest #Angiogenesis #Skinirritationtest #Invitroocularirritationtest

#invitro studies, #Animal cell culture,#Molecular Biology, #Western Blotting, # RT PCR, #Chemidoc, #Microbiology, #Cellular Biology, #Contract Research Organization, CRO, #R&D, #Internship, #Training, #Ph.D, #Research institute, #Neurologist, #Biomaterials, #Nanocomposites, #Nanoparticles, Nanoscience, #Gene expression, Protein expression, #Gene cloning, #Animal studies

🌟 Exciting News from molE@PoliTO 🌟 We are pleased to announce the publication of our latest research, conducted in collaboration with Fresenius Kabi, Redshiftbio, and Politecnico di Torino (molE Group). This study explores the challenging problem of peptide aggregation in biopharmaceutical development and neurodegenerative diseases. Our research combines computational simulations and experimental validation to uncover the aggregation mechanisms of glucagon, a peptide with a high tendency to aggregate. Key findings reveal that lactose and 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) have distinct effects on glucagon: 🧬 Lactose stabilizes glucagon by increasing its α-helical content. 🧪 2-HPβCD disrupts protein-protein interactions, effectively preserving the monomeric form of glucagon. Using microfluidic modulation spectroscopy (MMS), we confirmed that 2-HPβCD maintains the structural stability of glucagon, supporting its anti-aggregation properties. This research not only provides crucial insights into glucagon aggregation but also introduces a powerful tool for monitoring peptide aggregation, paving the way for innovative strategies in therapeutic peptide development. Read the full study here: https://lnkd.in/dGHmeufm #Peptide #Protein #MolecularDynamics #Biopharmaceuticals #NeurodegenerativeDiseases #ProteinAggregation #ScientificResearch #Mole #PolitecnicoDiTorino

🌟 Exciting News from molE@PoliTO 🌟 We are pleased to announce the publication of our latest research, conducted in collaboration with Fresenius Kabi, Redshiftbio, and Politecnico di Torino (molE Group). This study explores the challenging problem of peptide aggregation in biopharmaceutical development and neurodegenerative diseases. Our research combines computational simulations and experimental validation to uncover the aggregation mechanisms of glucagon, a peptide with a high tendency to aggregate. Key findings reveal that lactose and 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) have distinct effects on glucagon: 🧬 Lactose stabilizes glucagon by increasing its α-helical content. 🧪 2-HPβCD disrupts protein-protein interactions, effectively preserving the monomeric form of glucagon. Using microfluidic modulation spectroscopy (MMS), we confirmed that 2-HPβCD maintains the structural stability of glucagon, supporting its anti-aggregation properties. This research not only provides crucial insights into glucagon aggregation but also introduces a powerful tool for monitoring peptide aggregation, paving the way for innovative strategies in therapeutic peptide development. Read the full study here: https://lnkd.in/dxAd64D3 #Peptide #Protein #MolecularDynamics #Biopharmaceuticals #NeurodegenerativeDiseases #ProteinAggregation #ScientificResearch #Mole #PolitecnicoDiTorino

🔬 Exciting News Alert! 🔬 🚀 Introducing New Modalities (Track 1) for Oligonucleotide Therapeutics Xchange in Boston! 🚀 Join us for a day packed with insights, discussions, and networking opportunities at the forefront of Oligonucleotide Therapeutics. Here’s a sneak peek into what awaits you: Overcoming challenges in the utilization of novel self-amplifying RNA (saRNA) vaccines for emerging and endemic infections. 👤 Zhinan Xia, Chief Scientific Officer, Abimmune Bio New formats / chemical modifications for antisense therapeutics 👤 Vinod Vathipadiekal, Board Director, Aldebaran Therapeutics Access the full agenda & register for your COMPLIMENTARY pass! https://bit.ly/3wYHLnQ Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 Our Partners 🤝🏽 ChemGenes 🤝🏽 PolyPeptide Group 🤝🏽 Nitto Avecia 🤝🏽 WuXi Chemistry (WuXi STA & WuXi TIDES) 🤝🏽 Vazyme Biotech *Agenda subject to change #Biotechnology #Therapeutics #MedicalScience #Healthcare #RNAVaccines #NetworkingRoundtable #ScientificAdvancement #ResearchAndDevelopment #DrugDiscovery #BioPharma #LifeSciences #Genomics #GeneTherapy #PrecisionMedicine #DrugDevelopment #BiomedicalResearch #MedicalInnovation #PharmaIndustry #HealthTech #Biochemistry #MolecularBiology #ClinicalTrials #DrugDelivery #Immunotherapy #RegenerativeMedicine #HealthScience #DrugDesign #RNAtherapeutics #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass